论文部分内容阅读
背景:临床实验证明御风胶囊(黄芪、当归、川芎、远志、丹参等中药)组成有益气活血、祛淤生新的功效,其影响途径可能与血小板聚集功能和血浆中血栓素B,6-酮前列腺素F1α含量的变化有关。目的:观察御风胶囊对血小板聚集功能的影响及其作用机制。设计:随机对照动物实验。单位:哈尔滨医科大学大庆校区药理组。材料:实验于2000-05/2004-07在哈尔滨医科大学大庆校区药理实验室完成。选择Wistar雄性老年大鼠40只,平均鼠龄8～10周,平均体质量(550±150)g‘Wistar雄性青年大鼠8只,平均鼠龄4～6周,平均体质量(230±120)g。方法:Wistar青年雄性大鼠8只为青年对照组;40只老年大鼠为血淤模型,采用数字表法随机分为5组,每组8只,即阿司匹林组,御风胶囊(由黄芪、当归、川芎、远志、丹参组成,黑龙江中医药大学附属二院制剂室提供胶囊制剂)低剂量组、中剂量组、高剂量组和老年模型组。分别给予阿司匹林溶液5.5g/kg,御风胶囊0.33g/kg,0.66g/kg,1.32g/kg,老年模型组和青年对照组不给药。连续灌胃22d,2次/d,末次给药1h后,采用血小板聚集法和放免法测量血小板聚集功能和血浆中血栓素B2,6-酮列腺素F1α的含量。主要观察指标:血小板聚集功能;血栓素B2和6-酮列腺素F1α的含量及比值。结果:48只动物全部进入结果分析①老年模型组血小板聚集率均高于其他五组(P<0.01)。②御风胶囊高剂量组1min、5min和最大血小板聚集率均低于阿司匹林组,分别为(7.96±2.17),(6.38±1.66),(14.33±2.87)ng/L和(31.95±3.94),(35.29±6.54),(38.68±7.46)ng/L,(P<0.01);中剂量组5min血小板聚集低于阿司匹林组[(13.96±1.66),(35.29±6.54)ng/L,(P<0.01)]。③御风胶囊低剂量组、中剂量组、高剂量组、阿司匹林组、青年对照组血栓B2含量均低于老年模型组(P<0.01)。④御风胶囊高剂量组血栓B2低于低剂量组[(100.13±8.90),(127.00±20.99)ng/L,(P<0.01)]。⑤御风胶囊高剂量组、中剂量组、青年对照组血栓素B2/6-酮-前列腺素F1α均低于老年模型组[(0.62±0.17),(0.69±0.14),(1.75±0.17),(1.11±1.12)ng/L,(P<0.05)]。结论:御风胶囊高剂量、中剂量可降低血浆中血栓素B2含量和提高6-酮前列腺素F1α含量,改善两者比值,对保持血栓素B2/6-酮前列腺素F1α之间的平衡有显著作用。低剂量组亦有作用,但效果不如高、中剂量组,可认为有预防作用。
BACKGROUND: Clinical trials have demonstrated that Yufeng capsules (Huangxi, Chinese angelica, Rhizoma Chuanxiong, Polygala tenuifolia, Radix Salviae Miltiorrhiza and other traditional Chinese medicines) have beneficial effects on qi, blood circulation, and phlegm and stasis. Their effects may be related to platelet aggregation and plasma thromboxane B,6- Changes in ketoprostaglandin F1α content are related. Objective: To observe the effect of Yufeng Capsule on platelet aggregation and its mechanism of action. Design: Randomized controlled animal experiments. Unit: Department of Pharmacology, Daqing Campus, Harbin Medical University. MATERIALS: The experiment was performed at the Daqing Campus Pharmacology Laboratory of Harbin Medical University from May 2000 to July 2004. 40 Wistar male aged rats were selected and the average age of mice was 8 to 10 weeks. The average body weight was (550±150) g’Wistar male young male rats with an average age of 4 to 6 weeks. The average body weight was 230±120. )g. METHODS: Eight young male Wistar rats were used as a young control group; 40 elderly rats were modeled as blood stasis, and randomly assigned into five groups using a digital table method with 8 rats in each group, namely the aspirin group and Yufeng Capsule (by Huang Qi, Angelica, Chuanxiong, Polygala tenuifolia, Salvia Miltiorrhiza, and the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine Preparation Center provided capsule preparations: low-dose group, middle-dose group, high-dose group, and elderly model group. Aspirin solution 5.5g/kg, Yufeng capsule 0.33g/kg, 0.66g/kg, and 1.32g/kg were given respectively. The elderly model group and the young control group were not administered. After continuous intragastric administration for 22 days, 2 times/day, 1 hour after the last administration, platelet aggregation and radioimmunoassay were used to measure platelet aggregation and plasma thromboxane B2,6-ketoxin F1α levels. MAIN OUTCOME MEASURES: Platelet aggregation function; contents and ratios of thromboxane B2 and 6-ketoxin F1α. RESULTS: Forty-eight animals were all involved in the result analysis. 1 The platelet aggregation rate of the elderly model group was higher than that of the other five groups (P<0.01). 2 The high-dose group Yufeng capsule high-dose group 1min, 5min and the maximum platelet aggregation rate were lower than the aspirin group, respectively (7.96 ± 2.17), (6.38 ± 1.66), (14.33 ± 2.87) ng / L and (31.95 ± 3.94), (35.29±6.54), (38.68±7.46) ng/L, (P<0.01); 5min platelet aggregation in the middle dose group was lower than the aspirin group [(13.96±1.66), (35.29±6.54) ng/L, (P< 0.01)]. The blood thrombus B2 content in the low-dose group, middle-dose group, high-dose group, aspirin group and young control group of Yufeng Capsule was lower than that of the elderly model group (P<0.01). The thrombus B2 in the high-dose group was lower than the low-dose group [(100.13±8.90), (127.00±20.99) ng/L, (P<0.01)]. The blood thromboxane B2/6-keto-prostaglandin F1α in high-dose group, middle-dose group and young control group were lower than those in the elderly model group [(0.62±0.17), (0.69±0.14), (1.75±0.17) (1.11±1.12) ng/L, (P<0.05)]. Conclusion: Yufeng Capsule can reduce the content of thromboxane B2 in plasma and increase the content of 6-ketoprostaglandin F1α, improve the ratio between the two, and maintain the balance between thromboxane B2/6-keto-prostaglandin F1α. Significant works. The low-dose group also has a role, but the effect is not as good as the high- and middle-dose groups, and it can be considered as a preventive effect.